Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Viral Hepat ; 25(6): 649-660, 2018 06.
Artigo em Inglês | MEDLINE | ID: mdl-29316037

RESUMO

Hepatitis C virus (HCV) chronically infects 2%-3% of the world's population, causing liver disease and cancer with prolonged infection. The narrow host range of the virus, being restricted largely to human hepatocytes, has made the development of relevant models to evaluate the efficacy of vaccines a challenge. We have developed a novel approach to accomplish this by generating a murine hepatoma cell line stably expressing nonstructural HCV antigens which can be used in vitro or in vivo to test HCV vaccine efficacies. These HCV-recombinant hepatoma cells formed large solid-mass tumours when implanted into syngeneic mice, allowing us to test candidate HCV vaccines to demonstrate the development of an HCV-specific immune response that limited tumour growth. Using this model, we tested the therapeutic potential of recombinant anti-HCV-specific vaccines based on two fundamentally different attenuated pathogen vaccine systems-attenuated Salmonella and recombinant adenoviral vector based vaccine. While attenuated Salmonella that secreted HCV antigens limited growth of the HCV-recombinant tumours when used in a therapeutic vaccination trial, replication-competent but noninfectious adenovirus expressing nonstructural HCV antigens showed overall greater survival and reduced weight loss compared to non-replicating nondisseminating adenovirus. Our results demonstrate a model with anti-tumour responses to HCV nonstructural (NS) protein antigens and suggest that recombinant vaccine vectors should be explored as a therapeutic strategy for controlling HCV and HCV-associated cancers.


Assuntos
Carcinoma Hepatocelular/patologia , Modelos Animais de Doenças , Neoplasias Hepáticas/patologia , Animais , Antígenos Virais/biossíntese , Antígenos Virais/genética , Carcinoma Hepatocelular/terapia , Carcinoma Hepatocelular/virologia , Feminino , Expressão Gênica , Hepacivirus/genética , Hepatócitos/virologia , Neoplasias Hepáticas/terapia , Neoplasias Hepáticas/virologia , Camundongos Endogâmicos C57BL , Modelos Biológicos , Transplante de Neoplasias , Resultado do Tratamento , Vacinas Sintéticas/administração & dosagem , Vacinas Sintéticas/imunologia , Vacinas contra Hepatite Viral/administração & dosagem , Vacinas contra Hepatite Viral/imunologia , Proteínas não Estruturais Virais/biossíntese , Proteínas não Estruturais Virais/genética
4.
J Nucl Med ; 21(2): 135-8, 1980 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-7356751

RESUMO

A radiometric method, based on inhibition of 14CO2 release from bacterial metabolism of C-14-labeled glucose, was applied to test the susceptibility of urinary organisms to antibiotics. The testing was also carried out by the routine disc diffusion method after isolation of the organisms. Results of susceptibility to antibiotics could be obtained within 2 to 4 hr by the radiometric technique, compared with the 48 hr required for the disc method.


Assuntos
Anti-Infecciosos Urinários/farmacologia , Testes de Sensibilidade Microbiana/métodos , Infecções Urinárias/microbiologia , Bactérias/efeitos dos fármacos , Bactérias/metabolismo , Dióxido de Carbono/metabolismo , Radioisótopos de Carbono , Glucose/metabolismo , Humanos , Fatores de Tempo , Infecções Urinárias/tratamento farmacológico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...